Original Article
Copyright ©2010 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 21, 2010; 16(35): 4400-4409
Published online Sep 21, 2010. doi: 10.3748/wjg.v16.i35.4400
Table 2 Characteristics of 313 chronic hepatitis C genotype 2 patients treated with a combination of pegylated interferon plus ribavirin according to age (mean ± SD)
Group C (age < 65 yr) (n = 252)Group D (age65 yr) (n = 61)P-value
Age (yr)47.7 ± 10.469.2 ± 3.4< 0.001
Male/female124/12828/330.671
Body mass index (kg/m2)23.1 ± 3.522.8 ± 2.90.577
Prior IFN monotherapy, n (%)47 (18.7)16 (26.2)< 0.001
Prior combined IFN plus RBV treatment, n (%)5 (2.0)4 (6.6)0.056
Alanine aminotransferase (IU/L)79.9 ± 78.768.9 ± 52.90.821
γ-glutamyltranspeptidase (IU/L)55.8 ± 64.744.3 ± 34.70.937
Albumin (g/dL)4.2 ± 0.43.9 ± 0.5< 0.001
White blood cell count (/mm3)5276.3 ± 1636.34958.0 ± 1495.60.005
Hemoglobin (g/dL)14.1 ± 1.413.4 ± 1.3< 0.001
Platelet count (109/L)18.9 ± 6.315.6 ± 4.7< 0.001
Creatinine (mg/dL)0.8 ± 1.50.7 ± 0.20.581
Creatinine clearance (mL/min)112.1 ± 31.474.6 ± 17.2< 0.001
Serum HCV-RNA level (kIU/mL)1588.3 ± 1628.71195.4 ± 1645.50.038
Histological fibrosis< 0.001
F0/F1/F2/F3/F430/77/39/10/101/21/9/2/12